Updates in AL Amyloidosis: The Moffitt ExperienceMoffitt Grand RoundsJanuary, 22, 2021
Dr. Brandon Blue, MD
Conflict of Interest
2
I have no conflicts to disclose
Learning Objectives
3
• 1) Understand approach to diagnosis and evaluation of AL Amyloidosis
• 2) Review current standard of care in management of AL Amyloidosis
• 3) Discuss outcomes of AL Amyloidosis patients within Moffitt catchment area
Amyloidosisextracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of proteins
Amyloidosis
Robbins & Cotran, Pathologic Basis of Disease, 2015
• Presence of amyloid-related systemic syndrome (organ involvement)• Positive Congo red staining of tissue deposits• Evidence the amyloid is light-chain related• Evidence of monoclonal plasma cell proliferative disorder
Primary Systemic (AL) AmyloidosisDiagnostic Criteria
• Demonstrate amyloid tissue deposition• BMBX• Abdominal fat pad biopsy• Salivary gland biopsy• Nerve biopsy• Rectal biopsy• Renal biopsy• Endomyocardial biopsy• Liver biopsy• Skin biopsy
• Typing of amyloid deposits• Gold standard-mass spectrometry• Immunostaining with electron microscopy• Immunohistochemistry
Diagnosis
• Amyloid Panel• CBC with Diff/CMP• SPEP/Immunofixation• Free Light Chains• 24 hour urine protein/UPEP/UFIX• LDH, Uric Acid• PT/PTT• Beta-2 microglobulin• Troponin T• NT-ProBNP
• Other labs• Factor X if indicated• BNP for patients with renal failure
Diagnostic Workup
• Skeletal Survey• Orthostatic Vital Signs• Assessment of Cardiac Involvement
• EKG• Echo with Strain• Cardiac MRI –preferred
• Consider depending on organ involvement:• Endocrine Testing• EMG/NCS• PFTs• Abdominal imaging• Endoscopy
Diagnostic Workup
Organ Involvement with AL Amyloidosis in 1065 Patients
Milani, et al. Medit J Hematol Infect Dis 2018;10:e2018022.
Organ Involvement Criteria for Amyloidosis
STAGESurvival in patients not undergoing stem cell transplantation Survival in patients undergoing stem cell transplantation
Median (mos) 5-yr survival % Median (mos) 4-yr survival %
I (0 Points) 55 50 Not Reached 87
II (1 Point) 19 35 97 72
III (2 Points) 12 20 58 56
IV (3 Points) 5 15 22 46
Revised Mayo Prognostic Staging
• NT-Pro-BNP ≥ 1800 ng/L• Troponin T ≥ 0.025 mcg/L• Difference between involved/uninvolved serum free light chains
≥ 18 mg/dl1 point for each factor
Hematologic Response Criteria for Primary Amyloidosis
Organ Response Criteria for Primary Amyloidosis
• Good Risk patients (Excellent performance status, good renal function, troponin T < 0.06 ng/ml, NT-Pro BNP < 5000 ng/L)• Autologous Transplant
• Intermediate Risk (NT-Pro BNP < 8500): • Combination chemotherapy• Chemo then transplant if organ improvement• Select patients may proceed straight to transplant
• High Risk (NT-Pro BNP > 8500):• Chemotherapy (dose attenuated)
Therapy of Primary AmyloidosisRisk Adapted Therapy
Merlini, et al. Blood 2013;121:5124.
Therapy of Primary AmyloidosisStem Cell Transplantation-OS by hematologic CR
Sanchorawala. Hem Onc Clin NA, 2014; 28:1131.
Therapy of Primary AmyloidosisStem Cell Transplantation-OS by cardiac involvement
Sanchorawala. Hem Onc Clin NA, 2014; 28:1131.
Therapy of Primary AmyloidosisStem Cell Transplantation-OS by ≤2 versus >2 organs
Sanchorawala. Hem Onc Clin NA, 2014; 28:1131.
Therapy of Primary AmyloidosisChemotherapy
Mikhael, et al. Blood 2012;119:4391 ; Venner, et al. Blood 2012;119:4387.
• CyBorD regimen: high response rate• Short median follow-up (21 and 14 months)• Good patient tolerance• UK trial
• 66.5% 2-year PFS
Therapy of Primary AmyloidosisChemotherapy
Palladini et al. Blood 2015;126:612 .
• Upfront CyBorD-230 patients• Hematologic response rate 60% with 43% ≥ VGPR• Cardiac response 17% ; Renal response 25%• Lower response rate in stage III cardiac patients [NT-ProBNP >
8500] (42%, ≥ VGPR 23%)• Worse median OS 7 months for stage III cardiac patients• 55% survival at 3 years
Therapy of Primary AmyloidosisOverall Survival with CyBorD in 230 Untreated Patients
Palladini et al. Blood 2015;126:612 .
Therapy of Primary AmyloidosisHigh Risk Cardiac Patients
Wechalekar, et al. Blood 2013;121:3420.
• Consider retreatment with bortezomib-based regimen (or ixazomib) If not refractory to bortezomib
• Consider Mel/Dex if not refractory Alkylating agents• If refractory to bortezomib—options include:
• Daratumumab• Lenalidomide/Dex• Pomalidomide/Dex• Carfilzomib• Len/Cy/Dex or Thal/Cy/Dex• Bendamustine
Treatment of Recurrent Disease
• AL amyloid fibril deposition causes cardiac dysfunction• Amyloidogenic light chains:
• Cardiotoxic• Reduce contractility in cardiac myocytes• Cause early death in zebra fish• Reduces pharyngeal contractility in C. elegans
• Doxycycline• Interferes with amyloid fibril formation• Abrogates light chain toxicity• Improved OS in patients getting doxycycline ABX prophylaxis post-auto-transplant
compared with PCN
Doxycyline for Cardiac AL Amyloidosis
Kumar et al. Blood 120, 3138 (2012)
• Retrospective case control of chemo + doxycycline• 30 patients with cardiac AL matched with 73 controls (cardiac stage, NT-ProBNP, age,
dFLC)• Doxycycline 100 mg PO BID• Improved ORR and CR rate• Improved median OS
Doxycyline for Cardiac AL Amyloidosis
Wechalekar Blood Cancer Journal 7, e546 (2017)
Doxycyline(OS by Mayo Stage)
Wechalekar Blood Cancer Journal 7, e546 (2017)
Doxycycline(Subgroup treated with upfront bortezomib combinations)
Wechalekar Blood Cancer Journal 7, e546 (2017)
Is There A Role For Allogeneic Transplant?
Schonland et al. Blood. 2006;107(6):
mOS 42 monthsPFS 19 monthsCR 26%
TRM 40%4 patients died <100 days
Recent Updates in AL Amyloidosis
ANDROMEDA trial
30
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini,Efstathios Kastritis,Mathew S. Maurer,Jeffrey Zonder,Monique C. Minnema,Ashutosh D. Wechalekar,Arnaud Jaccard,Hans C. Lee,Naresh Bumma,Jonathan L. Kaufman,Eva Medvedova,Tibor Kovacsovics,Michael Rosenzweig,Vaishali Sanchorawala,Xiang Qin,Sandra Y. Vasey,Brendan M. Weiss,Jessica Vermeulen,Giampaolo Merlini,Raymond L. Comenzo, Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA, Blood, 2020,
Copyright © 2021 American Society of Hematology
Importance of Alkylating Agent and Proteasome
Inhibitor in AL Amyloidosis
Overall Survival Progression Free Survival
The Moffitt Experience
36
• Racial Disparities• Upfront Treatment• Doxycycline Use
Racial Disparities
Presented ASCO 2020
37
Racial Disparities in AL Amyloidosis
Upfront Treatment in AL Amyloidosis
Upfront Treatment in AL Amyloidosis
Doxycycline Use in AL Amyloidosis
Factor No Doxycycline usen=189
Doxycycline usen=20 P value
Clinical DateMale 10 (50%) 116 (61.4%) 0.345Age at diagnosis 64 (0.76) 62 (2.2) 0.256Date of diagnosis before 1/2014 83 (43.9%) 6 (30 %) 0.342Concurrent Multiple Myeloma 38 (20.3%) 6 (31.6%) 0.250African American 18 (10.7%) 2 (10.5%) 1.0Stage
Stage I 38 (27.5%) 2 (12.5%)
0.337Stage II 33 (23.9%) 3 (18.8%)
Stage III 40 (29.0%) 5 (31.3%)Stage IV 27 (19.6%) 6 (37.5%)
Biomarkers at time of diagnosiseGFR 54 (2.3) 53 (6.6) 0.887NT-pro-BNP 5699 (964) 5562 (1477) 0.962cTnT 0.09 (0.01) 0.14 (0.03) 0.19224 hr urine protein 64 (55) 644 (539) 0.017sFLC 799 (179) 776 (298) 0.968Bone Marrow Plasma Cell % 18 (1.4) 24 (5.2) 0.239FISH t(11;14) 25 (19.4%) 4 (36.4%) 0.239
First line Treatment data No treatment 17(9.0%) 2 (10.5%)
0.296
HD Mel + ASCT 16 (8.5%) 2(10.5%)AA based therapy 14 (7.4%) 1 (5.3%)PI based therapy 60 (31.7%) 2 (10.5%)
PI+AA based therapy 67 (35.4%) 9 (47.4%)Others 15 (7.9%) 3 (15.8%)
Hematologic responseNo response 26 (20%) 0 (0%)
0.145Partial response 51 (39.2%) 3 (30%)
Very good response 20 (15.4%) 4 (40%)Complete response 33 (25.4%) 3 (30%)
Organ responseNo response 65 (57%) 1 (33.3%)
0.579Response 49 (43%) 2 (66.7%)
ToxicityNo Toxicity 69 (57%) 5 (50%)
0.554Grade I 23 (19%) 2 (20%)
Grade II 16 (13.2%) 3 (30%)Grade III 12 (9.9%) 0 (0%)Grade IV 1 (0.8%) 0 (0%)
Doxycycline Use in AL Amyloidosis
Biochemical vs. organ R/PMedian (IQR) or percentage All (n = 69) Biochemical R/P (n = 29) Organ R/P (n = 40) P valueAt diagnosisAge (years) 62 (57-70) 62 (57-72) 64 (58-69) 0.892Male (%) 42 (60.9) 19 (65.5) 23 (57.5) 0.501Lambda light chain (%) 50 (72.5) 17 (58.6) 33 (82.5) 0.028Cardiac stage 2/3 (%) 37 (66.1) (n = 56) 16 (64.0) (n = 25) 21 (67.7) (n = 31) 0.769Cardiac stage 3 (%) 12 (21.4) (n = 56) 7 (28.0) (n = 25) 5 (16.1) (n = 31) 0.282Renal stage 2/3 (%) 43 (68.3) (n = 63) 15 (60.0) (n = 25) 28 (73.7) (n = 38) 0.254Renal stage 3 (%) 11 (17.5) (n = 63) 4 (16.0) (n = 25) 7 (18.4) (n = 38) 0.804Organ number >= 3 (%) 20 (29.0) 9 (31.0) 11 (27.5) 0.749Elevated LDH (%) 39 (67.2) (n = 58) 16 (66.7) (n = 24) 23 (67.6) (n = 34) 0.938Elevated B2MG (%) 42 (72.4) (n = 58) 16 (69.6) (n = 23) 26 (74.3) (n = 35) 0.694BMPC >= 20% (%) 18 (26.9) (n = 67) 5 (17.2) 13 (34.2) (n = 38) 0.121T (11;14) (%) 9 (17.0) (n = 53) 6 (25) (n = 24) 3 (10.3) (n = 29) 0.157dFLC (mg/L) 121.1 (26.8-751.3) (n = 64) 312.5 (88.1-1189.0) (n = 25) 73.0 (16.3-327.1) (n = 39) 0.028Low dFLC (< 50 mg/L) (%) 19 (29.7) (n = 64) 2 (8.0) (n = 25) 17 (43.6) (n = 39) 0.002Upfront therapyHDM/ASCT (%) 25 (36.2) 10 (34.5) 15 (37.5) 0.797PI-based regimen (%) 36 (52.2) 16 (55.2) 20 (50.0) 0.671Adequate hematological response (>= VGPR or R) (%) 41 (60.3) (n = 68) 16 (55.2) 25 (64.1) (n = 39) 0.457Organ response (%) 41 (60.3) (n = 68) 16 (55.2) 25 (64.1) (n = 39) 0.457At relapseTime from upfront to salvage (months) 22 (7-42) 22 (5-28) 21 (8-48) 0.211dFLC (mg/L) 90.3 (34.4-256.3) (n = 58) 150.9 (56.8-277.7) (n = 22) 80.7 (25.5-229.8) (n = 36) 0.288High risk dFLC progression (%) 30 (54.5) (n = 55) 10 (50) (n = 20) 20 (57.1) (n = 35) 0.609Salvage therapyPI-based regimen (%) 38 (55.1) 16 (55.2) 22 (55.0) 0.989Daratumumab-based regimen (%) 9 (13.0) 5 (17.2) 4 (10.0) 0.378
Factors predicting post-relapse survivalVariables OS2
Univariate Multivariate 1 (Organ) ** Multivariate 2 (Cardiac) **HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
At diagnosisAge (years) 0.987 (0.937-1.040) 0.635Male 0.500 (0.208-1.202) 0.121Lambda light chain 2.529 (0.744-8.602) 0.137Cardiac stage 2/3 2.934 (0.656-13.119) 0.159Renal stage 2/3 1.394 (0.501-3.876) 0.525Organ >= 3 0.770 (0.282-2.103) 0.61Elevated LDH 0.825 (0.288-2.364) 0.721Elevated B2MG 2.238 (0.664-7.850) 0.19BMPC >= 20% 5.800 (2.384-14.112) < 0.001 3.206 (1.283-8.012) 0.013 4.327 (1.713-10.925) 0.002T (11;14) 0.778 (0.174-3.469) 0.742Low dFLC (< 50 mg/L) 1.005 (0.404-2.502) 0.992Upfront therapyAdequate hematological response (>= VGPR or R) 0.628 (0.247-1.593) 0.327Organ response 0.581 (0.240-1.404) 0.227At relapseTime from upfront to salvage >= 24 (months) 0.409 (0.158-1.056) 0.065High risk dFLC progression 1.760 (0.667-4.647) 0.254Organ R/P * 7.581 (1.761-36.624) 0.007 5.506 (1.222-24.811) 0.026Cardiac R/P * 3.532 (1.453-8.585) 0.005 3.754 (1.461-9.642) 0.006Treatment sequencePI -> IMiD 1 1 1Others 0.129 (0.038-0.437) 0.001 0.234 (0.067-0.822) 0.023 0.149 (0.040-0.551) 0.004ASCT -> CyBorD/Dara, or PI -> Dara 0.025 (0.003-0.235) 0.001 0.051 (0.005-0.504) 0.011 0.034 (0.003-0.351) 0.005
Pe
rce
nt
su
rviv
al
0 2 4 4 8 7 2 9 6 1 2 0 1 4 4 1 6 80
2 5
5 0
7 5
1 0 0
B M P C > = 2 0 % (m e d ia n O S 2 1 6 .8 )
B M P C < 2 0 % (m e d ia n O S 2 N R )
p < 0 .0 0 0 1 Pe
rce
nt
su
rviv
al
0 2 4 4 8 7 2 9 6 1 2 0 1 4 4 1 6 80
2 5
5 0
7 5
1 0 0
O rg a n (m e d ia n O S 2 4 7 .7 )
B io c h e m ic a l (m e d ia n O S 2 N R )
p = 0 .0 0 1 4 Pe
rce
nt
su
rviv
al
0 2 4 4 8 7 2 9 6 1 2 0 1 4 4 1 6 80
2 5
5 0
7 5
1 0 0
C a rd ia c (m e d ia n O S 2 3 0 .7 )
O th e rs (m e d ia n O S 2 N R )
p = 0 .0 0 3 0 Pe
rce
nt
su
rviv
al
0 2 4 4 8 7 2 9 6 1 2 0 1 4 4 1 6 80
2 5
5 0
7 5
1 0 0
S e q 1 (m e d ia n O S 2 6 .1 )
S e q 2 (m e d ia n O S 2 6 0 .2 )
S e q 3 (m e d ia n O S 2 N R )
p < 0 .0 0 0 1
OS2: from salvage therapy to last follow up or death
OS1: from upfront therapy to last follow up or death
Pe
rce
nt
su
rviv
al
0 4 8 9 6 1 4 4 1 9 2 2 4 0 2 8 80
2 5
5 0
7 5
1 0 0
B M P C > = 2 0 % (m e d ia n O S 1 4 3 .9 )
B M P C < 2 0 % (m e d ia n O S 1 1 8 1 .0 )
p < 0 .0 0 0 1 Pe
rce
nt
su
rviv
al
0 4 8 9 6 1 4 4 1 9 2 2 4 00
2 5
5 0
7 5
1 0 0
O rg a n (m e d ia n O S 1 1 5 7 .9 )
B io c h e m ic a l (m e d ia n O S 1 N R )
p = 0 .0 0 3 8 Pe
rce
nt
su
rviv
al
0 4 8 9 6 1 4 4 1 9 2 2 4 00
2 5
5 0
7 5
1 0 0
C a rd ia c (m e d ia n O S 1 4 3 .9 )
O th e rs (m e d ia n O S 1 1 8 1 .0 )
p = 0 .0 0 0 8 Pe
rce
nt
su
rviv
al
0 4 8 9 6 1 4 4 1 9 2 2 4 0 2 8 80
2 5
5 0
7 5
1 0 0
S e q 1 (m e d ia n O S 1 3 0 .5 )
S e q 2 (m e d ia n O S 1 1 5 7 .9 )
S e q 3 (m e d ia n O S 1 2 1 2 .6 )
p < 0 .0 0 0 1
Next Steps
Moffitt Cancer Center Amyloid Center
• Cardiology• Neurology• Nephrology• Gastroenterology• Hepatology
• Heme/Onc/BMT• Pulmonology• Radiology• Pathology
• Multidisciplinary Approach
Thank you
49
Top Related